![]() |
Name |
2-ethoxycarbonyl-endocrocin
|
Molecular Formula | C18H14O7 | |
IUPAC Name* |
ethyl1,6,8-trihydroxy-3-methyl-9,10-dioxoanthracene-2-carboxylate
|
|
SMILES |
CCOC(=O)c1c(C)cc2c(c1O)C(=O)c1c(O)cc(O)cc1C2=O
|
|
InChI |
InChI=1S/C18H14O7/c1-3-25-18(24)12-7(2)4-9-14(16(12)22)17(23)13-10(15(9)21)5-8(19)6-11(13)20/h4-6,19-20,22H,3H2,1-2H3
|
|
InChIKey |
PNMZIDHAAOVWPT-UHFFFAOYSA-N
|
|
Synonyms |
NA
|
|
CAS | NA | |
PubChem CID | NA | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Molecular Weight: | 342.3 | ALogp: | 2.1 |
HBD: | 3 | HBA: | 7 |
Rotatable Bonds: | 2 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 121.1 | Aromatic Rings: | 3 |
Heavy Atoms: | 25 | QED Weighted: | 0.612 |
Caco-2 Permeability: | -5.285 | MDCK Permeability: | 0.00001500 |
Pgp-inhibitor: | 0.09 | Pgp-substrate: | 0.001 |
Human Intestinal Absorption (HIA): | 0.071 | 20% Bioavailability (F20%): | 0.204 |
30% Bioavailability (F30%): | 0.994 |
Blood-Brain-Barrier Penetration (BBB): | 0.021 | Plasma Protein Binding (PPB): | 100.06% |
Volume Distribution (VD): | 0.402 | Fu: | 1.57% |
CYP1A2-inhibitor: | 0.93 | CYP1A2-substrate: | 0.144 |
CYP2C19-inhibitor: | 0.137 | CYP2C19-substrate: | 0.055 |
CYP2C9-inhibitor: | 0.624 | CYP2C9-substrate: | 0.256 |
CYP2D6-inhibitor: | 0.357 | CYP2D6-substrate: | 0.153 |
CYP3A4-inhibitor: | 0.55 | CYP3A4-substrate: | 0.096 |
Clearance (CL): | 9.092 | Half-life (T1/2): | 0.192 |
hERG Blockers: | 0.035 | Human Hepatotoxicity (H-HT): | 0.033 |
Drug-inuced Liver Injury (DILI): | 0.938 | AMES Toxicity: | 0.779 |
Rat Oral Acute Toxicity: | 0.023 | Maximum Recommended Daily Dose: | 0.7 |
Skin Sensitization: | 0.178 | Carcinogencity: | 0.134 |
Eye Corrosion: | 0.003 | Eye Irritation: | 0.946 |
Respiratory Toxicity: | 0.038 |